Physician profile
Mitchell I Edelson
NPI 1255305546
$16,996.50
in general payments reported to CMS, 2019-2025
15 companies · $6,667 in 2025
The $6,667 reported for 2025 was more than what 88% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,338 · 2020: $127 · 2021: $2,021 · 2022: $2,738 · 2023: $517 · 2024: $588 · 2025: $6,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,175 · Food and Beverage: $1,513 · Travel and Lodging: $84.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,175.00 |
| Food and Beverage | $1,512.71 |
| Travel and Lodging | $84.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,638.95 | 2021-2025 | Zejula, Jemperli |
| Tesaro, INC. | $4,054.84 | 2019 | |
| Abbvie INC. | $3,992.12 | 2024-2025 | |
| Intuitive Surgical, INC. | $2,530.90 | 2022 | |
| Baxter Healthcare | $772.79 | 2019-2025 | Floseal, Tisseel, Perclot |
| Astrazeneca Pharmaceuticals LP | $320.38 | 2023-2024 | Lynparza |
| Eisai INC. | $257.40 | 2019-2025 | |
| Immunogen, INC. | $132.63 | 2023 | Elahere |
| Coopersurgical, INC. | $70.59 | 2021 | |
| Genmab U.S., INC. | $65.61 | 2023-2024 | Tivdak |
| Myriad Genetic Laboratories, INC. | $60.25 | 2024 | Myrisk, Precisetumor |
| Novocure INC. | $58.25 | 2020 | |
| Inspire Medical Systems, INC. | $24.34 | 2025 | Inspire |
| Covidien LP | $16.73 | 2020 | |
| Clovis Oncology, INC. | $0.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Edelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.